Search by Journal

The Japanese Society of Psychiatric Pharmacy

Volume , Issue suppl / 2021
English Article   Japanese Article
  • Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Japanese Article The fifth Japan mind Pharmaceutical Society general meeting, academic meeting Leap - With thanks to our forerunners greetings
神村英利
The Japanese Society of Psychiatric Pharmacy (suppl): 3-3, 2021.
Japanese Article Way ... reconsideration of the psychiatry clinical pharmacist
吉尾隆
The Japanese Society of Psychiatric Pharmacy (suppl): 28-28, 2021.
Japanese Article Education and study of the pharmacy
三島健一, 刃根菜七子
The Japanese Society of Psychiatric Pharmacy (suppl): 29-29, 2021.
Japanese Article Individualization dosage - of - lithium and the antimicrobial to apply clinical Pharmacometrics to in a mental pharmacy domain
辻泰弘
The Japanese Society of Psychiatric Pharmacy (suppl): 30-30, 2021.
Japanese Article The past, the present, the future of the term psychiatry pharmacist of the organizer
木藤弘子
The Japanese Society of Psychiatric Pharmacy (suppl): 31-31, 2021.
Japanese Article S1-1. Opening and psychiatry pharmacist ... of past ... drug control instruction duties of the psychiatry pharmacist
吉尾隆
The Japanese Society of Psychiatric Pharmacy (suppl): 32-32, 2021.
Japanese Article S1-2. ... which learns the present now in ... past, and thinks about the future of the psychiatry pharmacist
天正雅美
The Japanese Society of Psychiatric Pharmacy (suppl): 33-33, 2021.
Japanese Article S1-3. The future of the psychiatry pharmacist
谷藤弘淳
The Japanese Society of Psychiatric Pharmacy (suppl): 34-34, 2021.
Japanese Article It is ... from a viewpoint of each case conference ... hospital, drugstore pharmacist by the term expert pharmacist of the organizer
栗原正亮1), 別所千枝2)
The Japanese Society of Psychiatric Pharmacy (suppl): 35-35, 2021.
Japanese Article S2-1. Examine proper use ... illness of the psychiatry therapeutic drug; is ... through medicine cooperation
神村英利
The Japanese Society of Psychiatric Pharmacy (suppl): 36-36, 2021.
Japanese Article S2-2. It is ... through the case study by relation ... expert to patients with schizophrenia
神村英利
The Japanese Society of Psychiatric Pharmacy (suppl): 37-37, 2021.
Japanese Article S2-3. It is ... through the case study by relation ... expert to patients with schizophrenia
進健司
The Japanese Society of Psychiatric Pharmacy (suppl): 38-38, 2021.
Japanese Article S2-4. It is the medication counseling at ... health insurance pharmacy through the case study by relation ... expert to patients with schizophrenia
中田裕介
The Japanese Society of Psychiatric Pharmacy (suppl): 39-39, 2021.
Japanese Article S2-5. It is the approach to patients with schizophrenia in ... mental hospital through the case study by relation ... expert to patients with schizophrenia
出川えりか
The Japanese Society of Psychiatric Pharmacy (suppl): 40-40, 2021.
Japanese Article Effect on patients with mental disorder under the term COVID-19 situation of the organizer
柴田木綿
The Japanese Society of Psychiatric Pharmacy (suppl): 41-41, 2021.
Japanese Article S3-1. It is ... from the situation of effect on patients with mental disorder - psychiatrist under the COVID-19 situation
中尾智博
The Japanese Society of Psychiatric Pharmacy (suppl): 42-42, 2021.
Japanese Article S3-2. About the response to new coronavirus infection in the mental hospital
宮原佳希, 池内加代, 本多智子, 本多義治
The Japanese Society of Psychiatric Pharmacy (suppl): 43-43, 2021.
Japanese Article S3-3. Efforts of the ethical pharmacy under the COVID-19 situation
前原雅樹, 杉山正康
The Japanese Society of Psychiatric Pharmacy (suppl): 44-44, 2021.
Japanese Article We regard the role of problem - pharmacist as the current situation of regional alliances in the term psychiatric practice of the organizer
竹内尚子
The Japanese Society of Psychiatric Pharmacy (suppl): 45-45, 2021.
Japanese Article S4-1. The current situation and problem of the area inclusion care system in correspondence with a mental disorder
藤井千代
The Japanese Society of Psychiatric Pharmacy (suppl): 46-46, 2021.
Japanese Article S4-2. It is ... from position of ... hospital pharmacist about the cooperation with the health insurance pharmacy in our hospital
和田智仁
The Japanese Society of Psychiatric Pharmacy (suppl): 47-47, 2021.
Japanese Article S4-3. In an area a drugstore pharmacist with the need corresponding to the mental health
原和夫
The Japanese Society of Psychiatric Pharmacy (suppl): 48-48, 2021.
Japanese Article The document retrieval basics skill training
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 49-49, 2021.
Japanese Article It is useful for the cancellation that "was not appreciated" of the conversation! Motivation interview to learn happily
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 49-49, 2021.
Japanese Article EGUIDE project workshop for pharmacists
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 50-50, 2021.
Japanese Article Short time program based on initial matching - mental health first aid (MHFA) to a person with disorder of the mental health
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 50-50, 2021.
Japanese Article The 2nd Online Workshop on Antipsychotic Drug Reduction and Dosage Reduction
日本精神薬学会
The Japanese Society of Psychiatric Pharmacy (suppl): 51-51, 2021.
Japanese Article Development from the clinical question in the psychopathic ward to clinical studies
佐々木史香
The Japanese Society of Psychiatric Pharmacy (suppl): 52-52, 2021.
Japanese Article Study of schizophrenia treatment that aimed at the recovery
竹内一平
The Japanese Society of Psychiatric Pharmacy (suppl): 53-53, 2021.
Japanese Article O-1. Consideration ... about the comparison with 2018 of the benzodiazepine drugs prescription in the generalization of the prescription investigation of the prescription fact-finding (2020) about the medical therapy of patients with schizophrenia 1-2020 year and the inpatient
鈴木貴子1,2), 佐藤康一2), 宇野準二2), 高田憲一2), 北川航平2), 天正雅美2), 野田幸裕2), 加藤剛2), 梅田賢太2), 三輪高市2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 56-56, 2021.
Japanese Article O-2. It is - 2 from the investigation of prescription fact-finding (2020) - 88 institutions about the medical therapy of patients with schizophrenia of the whole country
高田憲一1,2), 鈴木貴子2), 佐藤康一2), 北川航平2), 宇野準二2), 加藤剛2), 梅田賢太2), 天正雅美2), 三輪高市2), 野田幸裕2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 56-56, 2021.
Japanese Article O-3. It is - 3 from the investigation of prescription fact-finding (2020) - 88 institutions about the medical therapy of patients with schizophrenia of the whole country
北川航平1,2), 加藤剛2), 鈴木貴子2), 佐藤康一2), 宇野準二2), 梅田賢太2), 高田憲一2), 三輪高市2), 野田幸裕2), 天正雅美2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 57-57, 2021.
Japanese Article O-4. BMI comparison ... of the prescription fact-finding 4 - inpatient and outpatient about the medical therapy of patients with schizophrenia
佐藤康一1,2), 鈴木貴子2), 高田憲一2), 北川航平2), 宇野準二2), 天正雅美2), 加藤剛2), 梅田賢太2), 三輪高市2), 野田幸裕2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 57-57, 2021.
Japanese Article O-5. It is - 5 from the investigation of prescription fact-finding (2020) - 80 institutions about the medical therapy of patients with schizophrenia of the whole country
宇野準二1,2), 鈴木貴子2), 北川航平2), 佐藤康一2), 高田憲一2), 天翔雅美2), 梅田賢太2), 加藤剛2), 三輪高市2), 野田幸裕2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 58-58, 2021.
Japanese Article O-6. It is ... about the prescription actual situation every prescription fact-finding (6) - inpatient ward classification about the medical therapy of patients with schizophrenia
天正雅美1,2), 佐藤康一2), 鈴木貴子2), 高田憲一2), 北川航平2), 宇野準二2), 加藤剛2), 梅田賢太2), 三輪高市2), 野田幸裕2), 吉尾隆2)
The Japanese Society of Psychiatric Pharmacy (suppl): 58-58, 2021.
Japanese Article O-7. Questionary survey for the use of blonanserin patch patients
福田のぞみ, 宇治宏美, 山田雅彦
The Japanese Society of Psychiatric Pharmacy (suppl): 59-59, 2021.
Japanese Article O-8. Investigation about the detachment of the blonanserin patch in the psychopathic ward
石川章1), 渡邊さつき2), 須貝昌平1), 水村亮介1), 眞壁秀樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 59-59, 2021.
Japanese Article O-9. Comparison ... of 1 mg of expression - starting dose of the irritability by the Perampanel and 2 mg
水村亮介1), 渡邊さつき2), 須貝昌平1), 石川章1), 倉持泉3), 村田佳子2), 岡島宏明2), 眞壁秀樹1)
The Japanese Society of Psychiatric Pharmacy (suppl): 60-60, 2021.
Japanese Article O-10. Efforts for the operation of blood Clozapine concentrations simulation
森田和弥1), 赤嶺由美子2), 宮崎賢三1), 小場佐仁美1), 牧坂夏実1), 阿部裕子1)
The Japanese Society of Psychiatric Pharmacy (suppl): 60-60, 2021.
Japanese Article O-11. Investigation about the usefulness of the discharge drug reporting book in the psychiatry
公文理紗子
The Japanese Society of Psychiatric Pharmacy (suppl): 61-61, 2021.
Japanese Article O-13. The actual situation and problem of the relation to the patients family by the psychiatry charge pharmacist particularly children
及川裕大, 櫻井浩子
The Japanese Society of Psychiatric Pharmacy (suppl): 61-61, 2021.
Japanese Article O-14. Convulsions and collaboration of the pharmacist that occurred in patients with schizophrenia
谷古宇美佳, 小原朋也, 谷口龍誠, 島崎良知
The Japanese Society of Psychiatric Pharmacy (suppl): 62-62, 2021.
Japanese Article O-15. Database study on sleep, active mass data acquired at medication and the wearable terminal of an antianxiety drug, the sleeping drug
齋藤知輝, 田中貴
The Japanese Society of Psychiatric Pharmacy (suppl): 62-62, 2021.
Japanese Article O-16. The taking combination attention drug situation investigation contraindicated to suvorexant and combination
篠島朋子1), 池内忠宏1), 佐々木史香1), 神村英利1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2021.
Japanese Article O-17. β-amyloid exposure astrocyte and the nerve cells which adhered have decreased excitable synapse transmission
大藪康平1), 清田寛樹2), 渡辺拓也2,3), 窪田香織2,3), 桂林秀太郎2), 神村英利1), 岩崎克典2,3)
The Japanese Society of Psychiatric Pharmacy (suppl): 63-63, 2021.
Japanese Article O-18. Effect of the ward pharmacist on medical therapy of the schizophrenia zone patients in the psychiatry emergency ward
黒川拓也1,2), 中野一也1), 宮部貴識1), 綾仁信貴2,3), 山野純弘3)
The Japanese Society of Psychiatric Pharmacy (suppl): 64-64, 2021.
Japanese Article O-19. Look at the single institution rear about the effect that a concomitant drug in the Clozapine treatment and a blood test give for treatment continuation; a mark observational study
廣田佳孝1), 青木勉2), 川島美智子1)
The Japanese Society of Psychiatric Pharmacy (suppl): 64-64, 2021.
Japanese Article O-20. Text analysis about the invention that a drugstore pharmacist practices for patients having a feeling of resistance towards taking antidepressant
庄司雅紀1), 藤原篤子2), 今福輪太郎3), 島田京司1), 恩田光子1)
The Japanese Society of Psychiatric Pharmacy (suppl): 65-65, 2021.
Japanese Article O-21. Study on learning effect of the psychiatry training in the pharmacy business training
築地茉莉子1), 石川雅之1,2), 渡辺健太1), 大久保正人1), 鈴木貴明1,2), 石井伊都子1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 65-65, 2021.
Japanese Article P-1. Research about the effect on cognitive function due to the merger situation of Alzheimer's dementia and diabetes in our hospital and diabetes
佐藤雅也1,3), 和田智仁1), 坂晋3), 藤田康平2), 三輪高市3)
The Japanese Society of Psychiatric Pharmacy (suppl): 66-66, 2021.
Japanese Article P-2. One ... which was effective for the medicine that it decreased by it of examination - benzodiazepine receptor agonist of the effect of the intervention of the cognitive-behavioral therapy by the pharmacist
柴田哲也, 森山俊恵, 中山今日子, 小平明子, 塚本康之
The Japanese Society of Psychiatric Pharmacy (suppl): 66-66, 2021.
Japanese Article P-3. Examination of the risk factor of the rehospitalization of patients with schizophrenia that received psychology educational program using the multivariate analysis
中野裕佳子1,2), 杉沢諭1,3), 栗原竜也4), 古屋宏章1,2), 永井努1,2), 黒沢雅広1,2), 常岡俊昭2,5), 稲本淳子5,6), 岩波明2,5)
The Japanese Society of Psychiatric Pharmacy (suppl): 67-67, 2021.
Japanese Article P-4. Risk factor of the central nervous system abnormality by the Clozapine
北川航平1), 植草秀介2), 松尾和廣2), 森山圭3), 山本達郎4), 矢田勇慈1), 児玉匡史1), 来住由樹1), 吉尾隆5,6)
The Japanese Society of Psychiatric Pharmacy (suppl): 67-67, 2021.
Japanese Article P-5. 2 case of treatment-resistant schizophrenia that we treated it by low-dose lithium carbonate combination for neutropenia during Clozapine administration and continued
渡辺研弥1), 野崎啓子2), 阿部裕也1), 一瀬瑞絵2), 佐藤亜希子2), 須藤孝浩1), 黒田純子1), 三浦至2), 矢部博興2)
The Japanese Society of Psychiatric Pharmacy (suppl): 68-68, 2021.
Japanese Article P-6. Study about the continuity of the stigma improvement effect by the patients contact type educational program to relieve the stigma for patients with schizophrenia of the pharmacist
大野英蓮1), 藤井知郎2), 室谷健太3), 半谷眞七子1), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 68-68, 2021.
Japanese Article P-7. Preliminary analysis of the association between medical treatment and pharmaceutical management of schizophrenia
麻那古信之1), 村田篤信2), 山本智也1), 長谷川尚美2), 肥田裕丈3), 井手健太4), 永井努5,6), 徳谷晃7), 清水善仁8), 松本純弥2), 三浦健一郎2), 渡邊衡一郎9), 稲田健10), 奥田真弘1), 橋本亮太2)
The Japanese Society of Psychiatric Pharmacy (suppl): 69-69, 2021.
Japanese Article P-8. Example that intervened for neurologic manifestation revival at paliperidone palmitate sustained-release parenteral injection introduction
須貝昌平, 渡邊さつき, 水村亮介, 石川章, 清水直樹, 新井久稔, 眞壁秀樹
The Japanese Society of Psychiatric Pharmacy (suppl): 69-69, 2021.
Japanese Article P-9. Analysis of the risk factor of the hypokalemia with the Yokukansan of patients with a mental disorder
保田和哉, 佐藤ありす, 土生陵太, 山田侑世, 池田龍二
The Japanese Society of Psychiatric Pharmacy (suppl): 70-70, 2021.
Japanese Article P-10. Investigation about the usability of the blonanserin patch in patients with schizophrenia
飯田優美1), 竹内一平1,3), 波多野正和1,2,4), 横井里奈1), 當真菜央1), 半谷眞七子1), 宇野準二3), 藤田潔3), 山田成樹2), 岩田仲生4), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 70-70, 2021.
Japanese Article P-11. About the effectiveness in the early introduction of clozapine which is treatment-resistant schizophrenia medicine
柴田真輝1), 波多野正和1,2), 竹内一平1,3), 半谷眞七子1), 宇野準二3), 山田成樹2), 藤田潔3), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 71-71, 2021.
Japanese Article P-12. About a factor influencing treatment preferences of the preparation for paliperidone palmitate three months of second generation antipsychotics in schizophrenia
加古結梨佳1), 竹内一平2), 半谷眞七子1), 宇野準二2), 藤田潔2), 亀井浩行1)
The Japanese Society of Psychiatric Pharmacy (suppl): 71-71, 2021.
Japanese Article P-13. Effect on internal secretion metabolism system of the sustained-release non-fixed form antipsychotics parenteral injection
鳥山梨佳子, 滝澤理貴
The Japanese Society of Psychiatric Pharmacy (suppl): 72-72, 2021.
Japanese Article P-14. A retrospective study on changes in sleep medication prescriptions following the introduction of lemborexant in psychiatric outpatients
久保慎司1), 小鳥居望1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 72-72, 2021.
Japanese Article P-15. Survey on prescription status of lemborexant tablets
浅田裕美子, 東向章, 中川文香, 織部敦志, 渡部秀幸
The Japanese Society of Psychiatric Pharmacy (suppl): 73-73, 2021.
Japanese Article P-16. Were the review of instructions and the abolition from the ward household medicine of the benzodiazepine operation-related sleeping drug effective in me at efforts - sleeplessness to fall fall accident prevention in the Fukuoka University Hospital?
大木伸泰1), 志垣都2,3), 佐々木史香1), 兼重晋1), 藤田昌樹3), 神村英利1,4)
The Japanese Society of Psychiatric Pharmacy (suppl): 73-73, 2021.
Japanese Article P-17. One patient who conducted formulation study in consideration of valproic acid and interaction of the lamotrigine
武田佳子, 五十嵐保陽, 西田恵美, 長郷あかね
The Japanese Society of Psychiatric Pharmacy (suppl): 74-74, 2021.
Japanese Article P-18. It is ... mainly on the situation of medication adequacy business - overlap medication by the cooperation of Tokorozawa-shi pharmacist society and Tokorozawa-shi
加藤剛1,2,3), 大塚正征2,3), 斉藤祐次2,3), 安達秀夫2,3), 鈴木順子4)
The Japanese Society of Psychiatric Pharmacy (suppl): 74-74, 2021.
Japanese Article P-19. The effect of the EGUIDE project on medical treatment of schizophrenia and the depression: From prescription investigation from 2016 through 2019
長谷川尚美1), 三浦健一郎1), 松本純弥1), 安田由華1,2), 稲田健3), 渡邊衡一郎4), 橋本亮太1)
The Japanese Society of Psychiatric Pharmacy (suppl): 75-75, 2021.
Japanese Article P-20. We look at the rear about the dose of the antipsychotics using the chlorpromazine reduced value system to automatically calculate and study a mark
村井華代1), 小原拓2), 鈴木貴子1), 菅野智行3)
The Japanese Society of Psychiatric Pharmacy (suppl): 75-75, 2021.
Japanese Article P-21. Fact-finding about the bringing medicine of the psychiatry domain in the acute phase hospital
内山将伸, 松尾宏一, 宮崎元康, 鵜木亜矢子, 今給黎修
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2021.
Japanese Article P-22. The expression situation and measures of the mental disorder with the Rotigotine patch
安高勇気1,2), 藤岡伸助3), 坪井義夫3), 神村英利1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 76-76, 2021.
Japanese Article P-23. Effect on change of the drug management instruction addition and pharmaceutical management
大塚誠, 今村健, 山廣胤之, 田渕知佳, 佐々木史香, 池内忠宏, 川原義弘, 兼重晋, 緒方憲太郎, 神村英利
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2021.
Japanese Article P-24. The intervention as the kidney disease medical treatment instruction person by the psychiatry pharmacist and the future prospects
渕上朋一1), 土井健志1), 中村賢広1), 芹田巧2), 松本俊二3), 畑田けい子3), 立木均3), 松本一隆3)
The Japanese Society of Psychiatric Pharmacy (suppl): 77-77, 2021.
Japanese Article P-25. Investigation about the usefulness of the prescription suggestion utilizing the evidence
阪岡倫行, 静村知恵, 桑原秀徳
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2021.
Japanese Article P-26. Look at the rear about the central nervous system side effect of the antihistamine in the cancer chemotherapy; mark investigation
大倉野将広1), 柿本秀樹1), 長郷あかね1,2), 内山将伸3), 川田哲史1), 真島宏太1), 角康隆1), 井上竜一1), 五十嵐保陽1), 武田佳子1), 池内忠宏1), 兼重晋1), 緒方憲太郎1,2), 神村英利1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 78-78, 2021.
Japanese Article P-27. Effect on pharmacist duties in the corona evil
笠原真理1), 坂井大地2), 竹村さゆり2), 山本勇樹2), 志田雅彦3), 鳥山梨佳子4), 滝澤理貴4), 中島舞5), 上野太佑6), 熊野智美7), 柳智之8), 森亨9), 高橋満里9), 佐藤実紀10), 石動郁子10)
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2021.
Japanese Article P-28. One patient who experienced accessory symptom by the mirogabalin internal use in the palliative care domain during sleep
川田哲史1), 大津友紀1,2), 藤金治雄1), 兼重晋1), 神村英利1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 79-79, 2021.
Japanese Article P-29. One patient who experienced the somnolence which continued by the mirogabalin internal use in the palliative care domain
井上貴文1), 川田哲史1), 大津友紀1,2), 山廣胤之1), 藤金治雄1), 兼重晋1), 神村英利1,2)
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2021.
Japanese Article P-30. The current situation investigation of expectation and the community medical care cooperation for the academic conference for Japanese mental Pharmaceutical Society members belonging to the health insurance pharmacy
有山智博1,2), 大向香織1,3), 栗原正亮1,4), 鈴木弘道1,5), 中田裕介1,6), 和田智仁1,7), 竹内尚子1,8)
The Japanese Society of Psychiatric Pharmacy (suppl): 80-80, 2021.
▲